Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 140,708 shares of the medical research company’s stock after acquiring an additional 8,180 shares during the quarter. Thermo Fisher Scientific accounts for 0.5% of Nisa Investment Advisors LLC’s holdings, making the stock its 29th largest position. Nisa Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $87,093,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. BDF Gestion purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $6,368,000. Lord Abbett & CO. LLC boosted its stake in shares of Thermo Fisher Scientific by 1.9% in the first quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company’s stock worth $45,478,000 after acquiring an additional 1,480 shares during the last quarter. Advisors Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 5.8% during the first quarter. Advisors Capital Management LLC now owns 111,169 shares of the medical research company’s stock worth $64,613,000 after buying an additional 6,089 shares in the last quarter. MV Capital Management Inc. raised its holdings in Thermo Fisher Scientific by 13.1% in the 1st quarter. MV Capital Management Inc. now owns 199 shares of the medical research company’s stock valued at $116,000 after acquiring an additional 23 shares during the last quarter. Finally, American National Bank & Trust Co. VA acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at approximately $7,306,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded down $2.44 during midday trading on Monday, hitting $551.94. 376,786 shares of the company’s stock were exchanged, compared to its average volume of 1,462,170. Thermo Fisher Scientific Inc. has a 12-month low of $420.21 and a 12-month high of $627.88. The stock has a market cap of $210.84 billion, a price-to-earnings ratio of 34.70, a price-to-earnings-growth ratio of 3.66 and a beta of 0.77. The firm’s 50 day simple moving average is $605.12 and its 200 day simple moving average is $584.07. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period last year, the business posted $5.69 EPS. The company’s revenue was up .2% on a year-over-year basis. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TMO. Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday. Evercore ISI cut their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday. Bank of America boosted their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a report on Monday, September 16th. UBS Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. Finally, Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $649.33.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.